Stock CANTA CANTARGIA AB
Add to a list
To use this feature you must be a member
Log inSign up

Cantargia AB Stock

Equities

CANTA

SE0006371126

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:42 2024-04-25 am EDT 		5-day change 1st Jan Change
3.47 SEK -2.80% Intraday chart for Cantargia AB -8.73% -7.17%
Apr. 17 Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition CI
Apr. 10 Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal CI

Financials

Sales 2024 * - Sales 2025 * 578M 53.17M Capitalization 656M 60.37M
Net income 2024 * -280M -25.78M Net income 2025 * -96M -8.84M EV / Sales 2024 * -
Net Debt 2024 * 56.6M 5.21M Net Debt 2025 * 657M 60.47M EV / Sales 2025 * 2.27 x
P/E ratio 2024 *
-1.65 x
P/E ratio 2025 *
-1.91 x
Employees 22
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.23%
More Fundamentals * Assessed data

Chart Cantargia AB

Dynamic Chart

Latest news about Cantargia AB

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition CI
Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal CI
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer CI
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis CI
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia CI
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis CI
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer CI
Transcript : Cantargia AB, 2023 Earnings Call, Feb 22, 2024
Cantargia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Cantargia Secures US Approval to Start Patient Recruitment for Pancreatic Cancer Therapy MT
Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab CI
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy CI
Cantargia Reports Phase I Clinical Progress in the CAN10 Project CI
Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10 CI
Cantargia Maintains Patent for Cancer Treatment Amid Withdrawal of Third-party Appeal MT
More news

Latest transcript on Cantargia AB

Logo Cantargia AB
Cantargia AB, 2023 Earnings Call, Feb 22, 2024
More transcripts

Analyst Recommendations on Cantargia AB

Cantargia AB Reports High Response Rates with CAN04 Combination Therapy in NSCLC and Presents Next Development Steps CI
More recommendations

Press releases Cantargia AB

Cantargia publishes Annual Report for 2023 AQ
Notice of annual general meeting in Cantargia AB (publ) AQ
Cantargia publishes new data on the CAN10 antibody, detailing its interaction with IL1RAP and functional inhibition AQ
Cantargia : Proposal regarding share-based incentive scheme PU
Cantargia : Proposal regarding guidelines for executive remuneration PU
More press releases

Quotes and Performance

1 day-4.40%
1 week-8.68%
Current month-0.52%
1 month+21.48%
3 months-3.29%
6 months-6.72%
Current year-7.12%
More quotes

Highs and lows

1 week
3.45
Extreme 3.446
3.83
1 month
2.81
Extreme 2.808
4.80
Current year
2.56
Extreme 2.564
4.80
1 year
2.56
Extreme 2.564
6.30
3 years
2.56
Extreme 2.564
35.78
5 years
2.56
Extreme 2.564
71.80
10 years
2.56
Extreme 2.564
71.80
More quotes

Managers and Directors - Cantargia AB

Managers TitleAgeSince
Göran Forsberg CEO
 Chief Executive Officer 61 14-07-08
Patrik Renblad DFI
 Director of Finance/CFO 54 23-06-14
David Liberg CTO
 Chief Tech/Sci/R&D Officer 55 14-12-31
Members of the board TitleAgeSince
Magnus Nilsson BRD
 Director/Board Member 68 21-05-25
Gunnar Magnus Modee Persson CHM
 Chairman 64 15-12-31
Damian Marron BRD
 Director/Board Member 62 21-05-25
More insiders

Quotes

Date Price Change Volume
24-04-25 3.47 -2.80% 331 410
24-04-24 3.57 -3.51% 285,166
24-04-23 3.7 -0.80% 380,337
24-04-22 3.73 +0.05% 478,715
24-04-19 3.728 -1.95% 267,532

Delayed Quote Nasdaq Stockholm, April 25, 2024 at 08:41 am EDT

More quotes

Company Profile

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Sector
Biotechnology & Medical Research
Calendar
2024-05-21 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.57 SEK
Average target price
12.67 SEK
Spread / Average Target
+254.81%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CANTARGIA AB Stock Cantargia AB
-7.12% 60.22M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.42B
ARGENX SE Stock argenx SE
+1.34% 22.2B
BIONTECH SE Stock BioNTech SE
-16.53% 21.23B
GENMAB A/S Stock Genmab A/S
-10.09% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CANTA Stock